↓ Skip to main content

Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia

Overview of attention for article published in Journal of Cancer Research and Clinical Oncology, March 2017
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age and source (56th percentile)

Mentioned by

twitter
3 X users

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
25 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia
Published in
Journal of Cancer Research and Clinical Oncology, March 2017
DOI 10.1007/s00432-017-2378-6
Pubmed ID
Authors

Hanna L. M. Rajala, Mohamed El Missiry, Anniina Ruusila, Perttu Koskenvesa, Tim H. Brümmendorf, Bjorn T. Gjertsen, Jeroen Janssen, Kourosh Lotfi, Berit Markevärn, Ulla Olsson-Strömberg, Leif Stenke, Jesper Stentoft, Johan Richter, Henrik Hjorth-Hansen, Anna Kreutzman, Satu Mustjoki

Abstract

Tyrosine kinase inhibitors (TKIs) have well-characterized immunomodulatory effects on T and NK cells, but the effects on the humoral immunity are less well known. In this project, we studied TKI-induced changes in B cell-mediated immunity. We collected peripheral blood (PB) and bone marrow (BM) samples from chronic myeloid leukemia (CML) patients before and during first-line imatinib (n = 20), dasatinib (n = 16), nilotinib (n = 8), and bosutinib (n = 12) treatment. Plasma immunoglobulin levels were measured, and different B cell populations in PB and BM were analyzed with flow cytometry. Imatinib treatment decreased plasma IgA and IgG levels, while dasatinib reduced IgM levels. At diagnosis, the proportion of patients with IgA, IgG, and IgM levels below the lower limit of normal (LLN) was 0, 11, and 6% of all CML patients, respectively, whereas at 12 months timepoint the proportions were 6% (p = 0.13), 31% (p = 0.042) and 28% (p = 0.0078). Lower initial Ig levels predisposed to the development of hypogammaglobulinemia during TKI therapy. Decreased Ig levels in imatinib-treated patients were associated with higher percentages of immature BM B cells. The patients, who had low Ig levels during the TKI therapy, had significantly more frequent minor infections during the follow-up compared with the patients with normal Ig values (33% vs. 3%, p = 0.0016). No severe infections were reported, except recurrent upper respiratory tract infections in one imatinib-treated patient, who developed severe hypogammaglobulinemia. TKI treatment decreases plasma Ig levels, which should be measured in patients with recurrent infections.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Finland 1 4%
Unknown 24 96%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 5 20%
Librarian 2 8%
Other 2 8%
Lecturer > Senior Lecturer 2 8%
Researcher 2 8%
Other 5 20%
Unknown 7 28%
Readers by discipline Count As %
Medicine and Dentistry 12 48%
Agricultural and Biological Sciences 2 8%
Pharmacology, Toxicology and Pharmaceutical Science 1 4%
Biochemistry, Genetics and Molecular Biology 1 4%
Immunology and Microbiology 1 4%
Other 1 4%
Unknown 7 28%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 November 2022.
All research outputs
#16,049,105
of 23,815,455 outputs
Outputs from Journal of Cancer Research and Clinical Oncology
#1,504
of 2,632 outputs
Outputs of similar age
#196,758
of 310,733 outputs
Outputs of similar age from Journal of Cancer Research and Clinical Oncology
#13
of 41 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,632 research outputs from this source. They receive a mean Attention Score of 3.6. This one is in the 34th percentile – i.e., 34% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 310,733 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 41 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.